Contineum Therapeutics, Inc. 4

CEO and President Carmine N. Stengone exercised 2,500 options and sold 2,500 shares of Contineum Therapeutics, Inc. Class A Common Stock at $16.00 per share, modestly reducing his direct holdings.

On July 8, 2026, Contineum Therapeutics, Inc. CEO and President Carmine N. Stengone exercised 2,500 stock options at an exercise price of approximately $1.01 per share, acquiring 2,500 shares of Class A Common Stock, and on the same day sold 2,500 shares of Class A Common Stock at $16.00 per share in a transaction effected under a Rule 10b5-1 trading plan adopted on September 23, 2025. The Form 4 shows his direct beneficial ownership decreasing from 19,717 shares to 17,217 shares after the sale, implying remaining holdings of about $275,000 based on the $16.00 share price. The options exercised were granted under the issuer’s 2012 Equity Incentive Plan and were fully vested, and the net effect of the paired exercise-and-sale was to monetize a portion of equity compensation while modestly reducing his net share position.

Filing Facts

CIK

1855175

Ticker

CTNM

Form

4

Source Type

fda

Accession

0001628280-26-047710

Alert Tier

6